 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.043.659 |
| Chemical and physical data | |
| Formula | C22H25N3O |
| Molar mass | 347.462 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Indoramin (trade namesBaratol andDoralese) is apiperidineantiadrenergic agent.
It is analpha-1 selective adrenoceptor antagonist[1] with direct myocardial depression action; therefore, it results in no reflextachycardia. It is also used inbenign prostatic hyperplasia (BPH).[2]
It is commonly synthesized fromtryptophol.[3]
Indoramin is commonly prescribed as 20 mg tablets when used in BPH.[4]
Drowsiness, dizziness, dry mouth, nasal congestion, headache, fatigue, weight gain,hypotension,postural hypotension, depression, problems with ejaculation, diarrhoea, nausea, increased need to pass urine, andpalpitations.[5]
Tryptamine andserotonin are naturally occurring indole ethylamino compounds with pronounced pharmacological activities. They have served as the inspiration for synthesis of numerous analogues.
One such study involved alkylation of 4-benzamidopyridine (2) with a bromoethyy compound (1) derived fromtryptophol, to give a quaternarypyridinium salt (3); this intermediate was in turn hydrogenated with aRaney nickel catalyst to give indoramine.[6][7]
On May 31, 2013, the French National Agency for the Safety of Medicines and Health Products (ANSM) concluded that the benefit/risk ratio of this product was unfavorable and withdrew Vidora's marketing authorization and recalled its batches from the market on June 3, 2013.[8]
 | Thisantihypertensive-related article is astub. You can help Wikipedia byexpanding it. |
